A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
BioNTech SE
BioNTech SE
National Institutes of Health Clinical Center (CC)
University of Florida
National Institutes of Health Clinical Center (CC)
DualityBio Inc.
Genfit
Intensity Therapeutics, Inc.
PureTech
Novo Nordisk A/S
Klus Pharma Inc.
Senhwa Biosciences, Inc.
University of Wisconsin, Madison
Northwestern University
National Institutes of Health Clinical Center (CC)